A multi-center randomized controlled trial presented at ESCMID Global 2026 reported that enhanced oral care can cut non-ventilator-associated hospital-acquired pneumonia risk by 60%. The study evaluated expanded oral hygiene protocols for hospitalized patients and found a reduction in NV-HAP incidence by more than half compared with control approaches. The report highlights the scale and randomized design, positioning the result as a potential shift in infection prevention practice for inpatient settings. Hospital-acquired pneumonia remains a major driver of morbidity, length of stay, and antimicrobial use, making effective prophylaxis clinically and operationally relevant. While the details of protocol components were not fully specified in the summary, the magnitude of effect suggests that standardized oral care could be a high-impact, low-cost intervention. Adoption will likely depend on feasibility across patient populations and integration into routine care bundles. For biotech-adjacent stakeholders, the trial also underscores ongoing demand for evidence-backed infection control strategies, which can complement device, diagnostic, and therapeutics offerings.